Jolt Health Inc, formerly known as Love Pharma, revealed that early-stage investor and seasoned entrepreneur Gerald Tritt is the company’s new chief executive officer and director, as it boosts it biotechnology, healthcare, and AI initiatives.
According to the Vancouver, British Columbia-based healthcare company, Tritt has a proven track record of success in the public markets and vast experience in various industries.
As an early stage-investor, Tritt has co-founded and co-owned several restaurant concepts, including one of Canada’s most prominent fast food chains, where he served as CEO. He has also consulted with international biotech companies in the health and wellness sector on their logistics and organizational structure, leveraging his extensive knowledge of e-commerce to expand their reach during the Covid-19 pandemic.
“We are delighted to welcome Mr Tritt to the Jolt Health team as our new CEO and Director,” said Jolt Health’s outgoing CEO Zachary Stadnyk.
“His diverse background in various industries, exceptional leadership skills, and his vast experience in the public markets make him the perfect candidate to lead Jolt Health’s new vision in healthcare, biotechnology and AI.”
Jolt said that Tritt has held senior positions in both national and international hospitality groups, giving him valuable leadership and operations skills that will prove essential in his role as Jolt’s CEO.
As an investor in multiple startups across different industries, he brings firsthand capital markets experience, an extensive network, corporate governance, and a strong private equity background to Jolt.
“I am thrilled to join Jolt Health and lead the company’s ambitious initiatives,” said Tritt. “I believe that the combination of Jolts’s existing expertise and resources, together with my experience and network, will enable us to develop innovative solutions and exciting investment opportunities.”
Tritt takes over immediately as CEO and director will work closely with the Jolt Health team to develop and execute the company’s strategic blueprint.
Jolt’s board and management team thanked Stadnyk for his instrumental role in publicly listing, financing and growing the company to this point.
He will remain a close advisor to the company on corporate finance and acquisition-related matters, said Jolt in a statement.
Jolt holds exclusive licenses for innovative pharmaceutical products in Europe and North America.
Contact the author Uttara Choudhury at uttara@proactiveinvestors.com
Follow her on Twitter: @UttaraProactive